03.07.2015 • News

Lonza Signs New Agreement with Alexion

Lonza has signed a new long-term product supply agreement with compatriot Alexion Pharmaceuticals.

Under the terms of the contract, an expansion of an existing manufacturing agreement, the Swiss life sciences group will build, own and operate a new toll manufacturing suite for the drugmaker beginning in 2017 at its Portsmouth, New Hampshire site in the US.

The new agreement will supplement existing production of Alexion products at multiple Lonza facilities and will enable Alexion to add dedicated product supply for 10 years.

Lonza said the expansion will allow customers increased access to its proven biological manufacturing and regulatory expertise, experienced global workforce and high level of focused customer service. The company can look back on more than two decades of worldwide manufacturing experience with mammalian biotherapeutics.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.